Grant: Discovery Grants Program - Individual
University of Guelph
$44,000.00
Elucidating the mechanism of avocatin B inhibition of very long chain acylCoA dehydrogenase
EF 2023-24
Résumé
Avocatin B (Avo) is an avocado-derived bioactive that was first discovered to be a potent inhibitor of fatty acid oxidation (FAO) in leukemia cells. Since that discovery, an NSERC DG supported several studies including the development of a sensitive method to detect it. We also showed that oral administration of Avo results in FAO inhibition and improved cellular metabolic effects in key normal (non-diseased) tissues including pancreatic, hepatic and skeletal muscle. Furthermore, a nutraceutical was created with standardized doses and tested in healthy human participants. Avo was well tolerated, not associated with any adverse-side effects and found circulating in peripheral blood. Ultimately, this is salient because avocados are widely consumed and a nutraceutical now contains this bioactive. Therefore, this work will have significant impact on Canadians. Avo is a 1:1 ratio of avocadene (Ene) and avocadyne (Yne) and current technology development exceeds our foundational scientific understanding of its mechanism of action. To develop a science-first nutraceutical, we seek a clearer understanding of how Ene and Yne alter cellular metabolic functions. Mechanistic studies have shown that Yne and Ene (when given individually) bind to and inhibit very long chain acyl-CoA dehydrogenase (VLCAD), an enzyme that catalyzes one of the first steps in long chain intra-mitochondrial FAO. Thus, the goals of this project are to understand how Yne and Ene bind to and inhibit VLCAD in normal (non-diseased) tissues and the implications of Yne/Ene ratios, which can vary between extractions, on VLCAD activity and FAO inhibition. To our knowledge, no nutraceutical is known to inhibit VLCAD, as such this fundamental research will provide valuable insights into this novel interaction. This proposal will use cell-free and cell-based (pancreatic and skeletal muscle) models to address 3 objectives. First, using biochemical approaches and site-directed mutagenesis we will determine the site on VLCAD where Yne and Ene bind. Second, we will determine the structure-function relationship between Yne, Ene and VLCAD binding. Here, we will test Yne and Ene structural analogues that vary based on carbon length, saturations, hydroxylations etc., to understand the impact on binding kinetics and VLCAD activity. In addition, we will determine if Yne and Ene act synergistically, additively or antagonistically in inhibiting VLCAD activity. Finally, we will determine the cellular effects of altered Yne/Ene ratios on VLCAD activity and how changes in these ratios impact overall VLCAD activity and FAO inhibition potency. Collectively, this work will have important implications for (i) development of products which contain the desired nutraceutical ingredient and (ii) understanding how cellular activity of these molecules translate to physiological function in healthy tissues.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2023-03935
Name nom
Spagnuolo, Paul
Department département
Food Science - Food Science
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2023
Award amount
44000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Not available
Research subject en
Non disponible
Research subject fr
Non disponible
Application title
Elucidating the mechanism of avocatin B inhibition of very long chain acylCoA dehydrogenase
Keyword
Avocadyne; Avocatin B; Binding kinetics; Fatty acid oxidation; Metabolism; Mitochondria; Very long chain acyl-coA dehydrogenase
Application summary
Avocatin B (Avo) is an avocado-derived bioactive that was first discovered to be a potent inhibitor of fatty acid oxidation (FAO) in leukemia cells. Since that discovery, an NSERC DG supported several studies including the development of a sensitive method to detect it. We also showed that oral administration of Avo results in FAO inhibition and improved cellular metabolic effects in key normal (non-diseased) tissues including pancreatic, hepatic and skeletal muscle. Furthermore, a nutraceutical was created with standardized doses and tested in healthy human participants. Avo was well tolerated, not associated with any adverse-side effects and found circulating in peripheral blood. Ultimately, this is salient because avocados are widely consumed and a nutraceutical now contains this bioactive. Therefore, this work will have significant impact on Canadians. Avo is a 1:1 ratio of avocadene (Ene) and avocadyne (Yne) and current technology development exceeds our foundational scientific understanding of its mechanism of action. To develop a science-first nutraceutical, we seek a clearer understanding of how Ene and Yne alter cellular metabolic functions. Mechanistic studies have shown that Yne and Ene (when given individually) bind to and inhibit very long chain acyl-CoA dehydrogenase (VLCAD), an enzyme that catalyzes one of the first steps in long chain intra-mitochondrial FAO. Thus, the goals of this project are to understand how Yne and Ene bind to and inhibit VLCAD in normal (non-diseased) tissues and the implications of Yne/Ene ratios, which can vary between extractions, on VLCAD activity and FAO inhibition. To our knowledge, no nutraceutical is known to inhibit VLCAD, as such this fundamental research will provide valuable insights into this novel interaction. This proposal will use cell-free and cell-based (pancreatic and skeletal muscle) models to address 3 objectives. First, using biochemical approaches and site-directed mutagenesis we will determine the site on VLCAD where Yne and Ene bind. Second, we will determine the structure-function relationship between Yne, Ene and VLCAD binding. Here, we will test Yne and Ene structural analogues that vary based on carbon length, saturations, hydroxylations etc., to understand the impact on binding kinetics and VLCAD activity. In addition, we will determine if Yne and Ene act synergistically, additively or antagonistically in inhibiting VLCAD activity. Finally, we will determine the cellular effects of altered Yne/Ene ratios on VLCAD activity and how changes in these ratios impact overall VLCAD activity and FAO inhibition potency. Collectively, this work will have important implications for (i) development of products which contain the desired nutraceutical ingredient and (ii) understanding how cellular activity of these molecules translate to physiological function in healthy tissues.